<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>DELAY IN DRUG MERGER</title>
    <meta content="MB233026" name="slug"/>
    <meta content="26" name="publication_day_of_month"/>
    <meta content="7" name="publication_month"/>
    <meta content="2000" name="publication_year"/>
    <meta content="Wednesday" name="publication_day_of_week"/>
    <meta content="Business/Financial Desk" name="dsk"/>
    <meta content="3" name="print_page_number"/>
    <meta content="C" name="print_section"/>
    <meta content="3" name="print_column"/>
    <meta content="Business" name="online_sections"/>
    <docdata>
      <doc-id id-string="1217843"/>
      <doc.copyright holder="The New York Times" year="2000"/>
      <series series.name="WORLD BUSINESS BRIEFING: EUROPE"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="indexing_service" type="descriptor">Mergers, Acquisitions and Divestitures</classifier>
        <classifier class="indexing_service" type="descriptor">Regulation and Deregulation of Industry</classifier>
        <classifier class="indexing_service" type="descriptor">Antitrust Actions and Laws</classifier>
        <org class="indexing_service">Glaxo Wellcome Plc</org>
        <org class="indexing_service">Smithkline Beecham Plc</org>
        <person class="indexing_service">Sorkin, Andrew Ross</person>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business/World Business</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Classifieds/Job Market/Job Categories/Pharmaceutical, Biotechnology and Science</classifier>
        <classifier class="online_producer" type="general_descriptor">Mergers, Acquisitions and Divestitures</classifier>
        <classifier class="online_producer" type="general_descriptor">Regulation and Deregulation of Industry</classifier>
        <classifier class="online_producer" type="general_descriptor">Antitrust Actions and Laws</classifier>
        <classifier class="online_producer" type="general_descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="online_producer" type="general_descriptor">Finances</classifier>
        <classifier class="online_producer" type="general_descriptor">Law and Legislation</classifier>
        <classifier class="online_producer" type="general_descriptor">Medicine and Health</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="20000726T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=9D01E5DE1E3AF935A15754C0A9669C8B63" item-length="129" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>DELAY IN DRUG MERGER</hl1>
      </hedline>
      <byline class="print_byline">By Andrew Ross Sorkin</byline>
      <byline class="normalized_byline">Sorkin, Andrew Ross</byline>
      <abstract>
        <p>Glaxo Wellcome PLC and SmithKline Beecham PLC says Glaxo's $76 billion acquisition of SmithKline will be delayed by about a month because deal is still being reviewed by US antitrust regulators; photo (M)</p>
      </abstract>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>Two British drug giants Glaxo Wellcome P.L.C. and SmithKline Beecham P.L.C. -- said the completion of Glaxo's $76 billion acquisition of SmithKline would be delayed by about a month because the deal is still being reviewed by United States antitrust regulators. Jean-Pierre Garnier, the chief executive of SmithKline, who will run the combined company, emphasized that the companies expect the deal to be completed and suggested the merger would now take effect by Sept. 25 instead of Aug. 21.</p>
        <p>Andrew Ross Sorkin (NYT)</p>
      </block>
      <block class="full_text">
        <p>Two British drug giants Glaxo Wellcome P.L.C. and SmithKline Beecham P.L.C. -- said the completion of Glaxo's $76 billion acquisition of SmithKline would be delayed by about a month because the deal is still being reviewed by United States antitrust regulators. Jean-Pierre Garnier, the chief executive of SmithKline, who will run the combined company, emphasized that the companies expect the deal to be completed and suggested the merger would now take effect by Sept. 25 instead of Aug. 21.</p>
        <p>Andrew Ross Sorkin (NYT)</p>
        <p>WORLD BUSINESS BRIEFING: EUROPE</p>
      </block>
    </body.content>
  </body>
</nitf>
